Notch inhibition, together with a potent TGFβ antagonism as we reported [42], may underlie the therapeutic effects of CM272 on liver fibrocystic disease and carcinogenic progression [31,44]. The gene discussed is TGFB1; the disease is autosomal dominant polycystic liver disease.